EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, WuXi Biologics (Cayman)'s Enterprise Value is HK$67,749 Mil.
WuXi Biologics (Cayman)'s Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-344 Mil. Therefore, WuXi Biologics (Cayman)'s EV-to-FCF for today is -196.95.
The historical rank and industry rank for WuXi Biologics (Cayman)'s EV-to-FCF or its related term are showing as below:
HKSE:02269'
s EV-to-FCF Range Over the Past 10 Years
Min: -861.18 Med: -91.11 Max: 261.43
Current: -196.95
During the past 10 years, the highest EV-to-FCF of WuXi Biologics (Cayman) was 261.43. The lowest was -861.18. And the median was -91.11.
HKSE:02269's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 8.19
vs HKSE:02269: -196.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of WuXi Biologics (Cayman)'s EV-to-FCF
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman)'s EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s EV-to-FCF distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s EV-to-FCF falls into.
WuXi Biologics (Cayman)'s current Enterprise Value is HK$67,749 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-344 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi Biologics (Cayman)'s PE Ratio (TTM) for today is calculated as:
WuXi Biologics (Cayman)'s share price for today is HK$17.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
WuXi Biologics (Cayman) EV-to-FCF Related Terms
Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02269 has been successfully added to your 